ArticleTranslational cancer research2026
Potential benefits of local radiotherapy in addition to adjuvant chemotherapy in female patients with triple-negative breast cancer in the absence of distant metastases: a SEER database analysis.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is no consensus on the advisability of additional supplementation with local radiotherapy in non-metastatic triple-negative breast cancer (TNBC) patients. The present study is the first analysis to construct a risk-scoring model to determine prognosis for TNBC without distant metastases, with a view to identifying groups for whom local radiotherapy would be of benefit. Methods: Cases of female patients diagnosed with non-metastatic TNBC patients who received adjuvant chemotherapy were extracted from Surveillance Epidemiology and End Results (SEER) database. Breast cancer-specific death (BCSD) was used as the primary prognostic indicator; sub-distribution hazard ratio (sHR) with 95% confidence interval (CI) was used to analyze the effect of radiotherapy with risk-stratification. Differences were considered statistically significant if P≤0.05. Results: A total of 19,371 patients were enrolled. Cumulative incidence function and sub-distribution hazard function showed that year of diagnosis, race, grade, lymph node (N) stage, primary site, lymph node ratio and tumor size were all associated with the probability of cancer-specific death (P<0.05). As regards BCSD, there was no survival benefit in receiving radiotherapy for low-risk (score ≤122) patients (sHR =0.839, 95% CI: 0.69-1.02, P=0.08), but radiotherapy improved survival for medium- and high-risk (score >122) groups (medium-risk: sHR =0.801, 95% CI: 0.682-0.941, P=0.007; high-risk: sHR =0.618, 95% CI: 0.516-0.74, P<0.001). Conclusions: A novel risk scoring system was constructed based on the results of the survival nomogram to screen for medium-high risk patients for whom radiotherapy may bring additional benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.